RBC raises estimates for Cubist

RBC analyst Jason Kantor said that strong IMS sales estimates and positive comments from two infectious disease specialists on a conference call support its bullish outlook and increased sales forecasts for Cubist Pharmaceuticals' Cubicin. Incremental positive comments included ongoing use of higher-dose regimens and growing positive experiences in osteomyelitis. IMS reported robust April sales as the best month ever, prompting RBC to raise its Q2 sales estimate to $45.5 million from $43 million. It also raised its price target to $33 from $25 based on its increased positive outlook. Shares of the company were down $2.36 or 9.07%, at $23.67 on volume of 5,015,197 shares. Three-month running averages are at 900,752. (Nasdaq: CBST)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.